Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma

Journal of Controlled Release

Volumn 208, Issue , 2015, Pages 52-58

  Mastria, Eric M ^a   Chen, Mingnan ^a,e   McDaniel, Jonathan R ^a,f   Li, Xinghai ^a   Hyun, Jinho ^b   Dewhirst, Mark W ^a,c   Chilkoti, Ashutosh ^a,d  

^a Duke University   (United States)

^b Seoul National University   (South Korea)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f The University of Texas at Austin   (United States)

Author keywords

Cancer; Delivery vehicle; Doxorubicin; Metastasis; Nanoparticle; Recombinant polypeptide

Indexed keywords

BIOLOGICAL ORGANS; DISEASES; DRUG DELIVERY; DRUG THERAPY; ENZYME INHIBITION; NANOPARTICLES; PATHOLOGY;

CANCER; DELIVERY VEHICLE; DOXORUBICIN; METASTASIS; RECOMBINANT POLYPEPTIDES;

TUMORS;

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; NANOPARTICLE; PEPTIDE;

ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CARCINOMA; CARCINOMA, LEWIS LUNG; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HALF LIFE TIME; MAXIMUM TOLERATED DOSE; MOUSE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; CARCINOMA; CARCINOMA, LEWIS LUNG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HALF-LIFE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PEPTIDES; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

EID: 84939974112     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.01.033     Document Type: Article

References (26)

1. J. MacKay, M. Chen, J. McDaniel, W. Liu, A. Simnick, and A. Chilkoti Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection Nat. Mater. 8 2009 993 999 10.1038/nmat2569
2. D. Peer, J. Karp, S. Hong, O. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760 10.1038/nnano.2007.387
3. M. Davis, Z. Chen, and D. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782 10.1038/nrd2614
4. N. Kamaly, Z. Xiao, P. Valencia, A. Radovic-Moreno, and O. Farokhzad Targeted polymeric therapeutic nanoparticles: design, development and clinical translation Chem. Soc. Rev. 41 2012 2971 3010 10.1039/c2cs15344k
5. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701 10.1038/nrc1958
6. S.R. Croy, and G.S. Kwon Polymeric micelles for drug delivery Curr. Pharm. Des 12 2006 4669 4684
7. P. Brusa, M.L. Immordino, F. Rocco, and L. Cattel Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs Anticancer Res. 27 2007 195 199 (published online 2007/03/14)
8. J. Fassberg, and V.J. Stella A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J. Pharm. Sci. 81 1992 676 684 10.1002/jps.2600810718 (published online 1992/07/01)
9. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284 10.1016/S0168-3659(99)00248-5
10. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360 10.1038/nrd1088
11. J.R. McDaniel, S.R. MacEwan, M. Dewhirst, and A. Chilkoti Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia J. Control. Release 159 2012 362 367 10.1016/j.jconrel.2012.02.030
12. P. Mehlen, and A. Puisieux Metastasis: a question of life or death Nat. Rev. Cancer 6 2006 449 458 10.1038/nrc1886
13. D. Meyer, and A. Chilkoti Purification of recombinant proteins by fusion with thermally-responsive polypeptides Nat. Biotechnol. 17 1999 1112 1115 10.1038/15100
14. A. Gabizon, D. Tzemach, L. Mak, M. Bronstein, and A.T. Horowitz Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models J. Drug Target. 10 2002 539 548 10.1080/1061186021000072447 published online 2003/04/10
15. D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, and G. Scambia Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) Ann. Oncol. 18 2007 1159 1164
16. B. Pulaski, and S. Ostrand-Rosenberg Mouse 4T1 breast tumor model John E. Coligan, Current Protocols in Immunology 2001 10.1002/0471142735.im2002s39 (Chapter 20)
17. Z.-G. Gao, L. Tian, J. Hu, I.-S. Park, and Y. Bae Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles J. Control. Release 152 2011 84 89 10.1016/j.jconrel.2011.01.021
18. Y. Yang, D. Pan, K. Luo, L. Li, and Z. Gu Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy Biomaterials 2013 10.1016/j.biomaterials.2013.07.037
19. Z. Dong, R. Radinsky, D. Fan, R. Tsan, C. Bucana, C. Wilmanns, and I. Fidler Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells J. Natl. Cancer Inst. 86 1994 913 920 10.1093/jnci/86.12.913
20. M. Bibby Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages Eur. J. Cancer 40 2004 852 857 10.1016/j.ejca.2003.11.021
21. Y. Yoshimoto, M. Kawada, D. Ikeda, and M. Ishizuka Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo Int. Immunopharmacol. 5 2005 281 288 10.1016/j.intimp.2004.09.032
22. 4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery Int. J. Nanomedicine 7 2012 1697 1708 10.2147/ijn.s28629
23. J. Joyce, and J. Pollard Microenvironmental regulation of metastasis Nat. Rev. Cancer 9 2009 239 252 10.1038/nrc2618
24. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187 10.1016/j.jconrel.2011.09.063
25. A. Schroeder, D.A. Heller, M.M. Winslow, J.E. Dahlman, G.W. Pratt, R. Langer, T. Jacks, and D.G. Anderson Treating metastatic cancer with nanotechnology Nat. Rev. Cancer 12 2012 39 50 10.1038/nrc3180
26. H.M. Kuerer, L.A. Newman, T.L. Smith, F.C. Ames, K.K. Hunt, K. Dhingra, R.L. Theriault, G. Singh, S.M. Binkley, N. Sneige, T.A. Buchholz, M.I. Ross, M.D. McNeese, A.U. Buzdar, G.N. Hortobagyi, and S.E. Singletary Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J. Clin. Oncol. 17 1999 460 469